Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 282-292

  Masliah, Eliezer ^a,b,c   Hansen, Lawrence A ^a,b   Rockenstein, Edward ^a   Hashimoto, Makoto ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

synuclein; synuclein; Alzheimer's disease; Lewy body disease; Parkinson's disease; Transgenic mouse

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIOXIDANT; ATROPINE; BETA SYNUCLEIN; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME C; DOPAMINE RECEPTOR STIMULATING AGENT; FENCLONINE; LEVODOPA; METIROSINE; NEUROTROPHIC FACTOR; PERGOLIDE; PLATELET DERIVED GROWTH FACTOR B;

ALZHEIMER DISEASE; DIFFUSE LEWY BODY DISEASE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; TRANSGENIC MOUSE;

EID: 0036660268     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10082     Document Type: Review

References (108)

1. Alves Da Costa C, Ancolio K, Cheeler F. 2000. Wild-type but not Parkinson's disease-related ala-53→ Thr mutant alpha synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 275:24065-24069.
2. Armstrong R, Cairns N, Lantos P. 2000. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement Geriatr Cogn Disord 11:187-192.
3. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868.
4. Citrou M, Oltersdorf T, Haass C, McConlogue L, Hung A, Seubert P, Vigo-Pelfrey C, Liberburg I, Selkoe D. 1992. Mutation in the b-amyloid precursor protein in familial Alzheimer's disease increases b-protein production. Nature 360:672-674.
5. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Subert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Hong Y, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St. George Hyslop P, Selkoe D. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med 3:67-72.
6. Clark R, Goate A. 1993. Molecular genetics of Alzheimer's disease. Arch Neurol 50:1164-1172.
7. Conway K, Harper J, Lansbury P. 1998. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Med 4:1318-1320.
8. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. 2000. Acceleration of oligomerization not fibrillization, is a shared property of both alpha-synuclein mutations linked to earlyonset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-576.
9. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-1349.
10. Davidson W, Jonas A, Clayton D, George J. 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443-9449.
11. Dickson D, Crystal H, Mattiace L, Kress Y, Schwagerl A, Ksiezak-Reding H, Davies P, Yen S-HC. 1989. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 78:572-584.
12. Dickson D, Ruan D, Crystal H, Mark M, Davies P, Kress Y, Yen S-H. 1991. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 41:1402-1409.
13. El-Agnaf O, Irvine G. 2000. Review: Formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J Struct Biol 130:300-309.
14. El-Agnaf O, Mahil D, Patel B, Austen B. 2000. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 273:1003-1007.
15. Feany M, Bender W. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-398.
16. Ferrigno P, Silver P. 2000. Polyglutamine expansions: proteolysis, chaperones, and the dangers of promiscuity. Neuron 26:9-12.
17. Forloni G, Bertani I, Calella A, Thaler F, Invernizzi R. 2000. Alphasynuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 47:632-640.
18. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
19. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495.
20. Halliday G, Brooks W, Arthur H, Creasey H, Broe G. 1997. Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neurosci Lett 227:49-52.
21. Hamilton RL, 2000. Lewy bodies in Alzheimer's disease: a neuropatbological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378-384.
22. Hansen L. 1997. The Lewy body variant of Alzheimer disease. J Neural Transm 51:111-121.
23. Hansen L, Masliah E, Terry R. 1989. A neuropathologic subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 78:194-201.
24. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay M, Hofstetter R, Klauber M. 1990. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40:1-7.
25. Hansen L, Masliah E, Quijada-Fawcett S, Rexin D. 1991. Entorhinal neurofibrillary tangles in Alzheimer disease with Lewy bodies. NeurosciLett 129:269-272.
26. Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. 1999. Interaction between Abeta(1-42) and Abeta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 38:15514-15521.
27. Hashimoto M, Masliah E, 1999. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 9:707-720.
28. Hashimoto M, Hernandez-Ruiz S, Hsu L, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. 1998. Human recombinant NACP/a-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res 799:301-306.
29. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. 1999a. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J Biol Chem 274:28849-28852.
30. Hashimoto M, Hsu L, Xia Y, Takeda A, Sundsmo M, Masliah E. 1999b. Oxidative stress induces amyloid-like aggregate formation of NACP/a-synuclein in vitro. Neuro report 10:717-721.
31. Hashimnoto M, Rockenstein E, Mante M, Mallory M, Masliah E. 2001. beta-synuclein inhibits alpha-synuclein aggregation. A possible role as an anti-Parkinsonian factor. Neuron 32:213-223.
32. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes A, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y. 1998. Point mutations (Thr240Arg and AIa311Stop) in the Parkin gene. Biochem Biophys Res Commun 249:754-758.
33. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E. 2000. a-Synuclein promotes mitochondrial deficiencies and oxidative stress. Am J Pathol 157:401-410.
34. Irizarry M, Growdon W, Gomez-Isla T, Newell K, George J; Clayton D, Hyman B. 1998. Nigral and cortical Lewy, bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp NeuroI 57:334-337.
35. Iwai A. 2000. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 1502:95-109.
36. Jakes R, Spillantini M, Goedert M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett 345:27-32.
37. Jensen P, Hojrup P, Hager H, Nielsen M, Jacobsen L, Olesen O, Gliemann J, Jakes R. 1997. Binding of Ab to a- and b-synucleins: identification of segments in a-synuclein/NAC precursor that bind Ab and NAC. Biochem J 323:539-546.
38. Jia T, Liu YE, Liu J, Shi YE. 1999. Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res 59:742-747.
39. Jo E, McLaurin J, Yip C, St.George-Hyslop P, Graser P. 2000. Alpha-synuclein membrane iteractions and lipid specificity. J Biol Chem 275:34328-34334.
40. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C. 2001. Selective insolubility, of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-2225.
41. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T. 2001. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417:59-67.
42. Kanda S, Bishop J, Eglitis M, Yang Y, Mouradian M. 2000. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97:279-284.
43. Katzman R, Saitoh T, 1991. Advances in Alzheimer's disease. FASEB J 5:278-286.
44. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
45. Klein A, Kowall N, Ferrante R. 1999. Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. Ann NY Acad Sci 893:314-320.
46. Koo E, Lansbury PJ, Kelly J, 1999. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96:9989-9990.
47. Kosaka K. 1978. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol (Berl) 42:127-134.
48. Kosaka K, Yoshimura M, Ikeda K, Budka H. 1984. Diffuse type of Lewy body disease. Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease? Clin Neuropathol 3:183-192.
49. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen J, Schols L, Reiss O. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinsons's disease. Nat Genet 18:106-108.
50. Langston JW, Langston EB, Irwin I, 1984. MPTP-induced parkinsonism in human and non-human primates: clinical and experimental aspects. Acta Neurol Scand Suppl 100:49-54.
51. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. 2002. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 277:5411-5417.
52. Leng Y, Chase TN, Bennett MC. 2001. Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 276:28212-28218:
53. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
54. Lin H, Bhatia R, Lal R. 2001. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. Faseb J 15:2433-2444.
55. Lippa C, Fujiwara H, Mann D, Giasson B, Baba M, Schmidt M, Nee L, O'Connell B, Pollen D, St.George-Hyslop P, Ghetti P, Ghetti B, Nochlon D, Bird TD, Cairns NJ, Lee V-M, Iwatsubo T, Trojanowski JQ. 1998. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365-1370.
56. Lippa C, Ozawa K, Mann D, Ishii K, Smith T, Arawaka S, Mori H. 1999. Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer diseaes. Arch Neurol 56:1111-1118.
57. Mann D, Brown S, Owen F, Baba M, Iwatsubo T. 1998. Amyloid beta protein (A beta) deposition in dementia Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. NeuropathoI Appl Neurobiol 24:187-194.
58. Masliah E, 2000a. The role of synaptic proteins in Alzheimer's disease. Ann NY Acad Sci 924:68-75.
59. Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. 1996. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 148:201-210.
60. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara, Sisk A, Mucke L. 2000b. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287:1265-1269.
61. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L, 2001. beta-Amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 98:12245-12250
62. Mattson M, Begley J, Mark R, Furukawa K. 1997. Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res 771:147-153.
63. McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen L, Salmon D, Lowe J, Mirra S, Byrne E, Quinn N, Edwardson J, Ince P, Bergeron C, Burns A, Miller B, Lovestone S, Collerton D, Jansen E, de Vos R, Wilcock G, Jellinger K, Perry R. 1996. Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop Neurology 47:1113-1124.
64. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K. 1993. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217:1057-1063.
65. Narayanan V, Scarlata S. 2001. Membrane binding and selfassociation of alpha-synucleins. Biochemistry 40:9927-9934.
66. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. 1999. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274:9843-9846.
67. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle P, Haass C. 2000. Consitutive phosphorylation of the Parkinson's disease associated α-synuclein. J Biol Chem 275:390-397.
68. Osterova-Golts N, Petrucelli L, Hardy J, Lee J, Farer M, Wolozin B, 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
69. Paik S, Lee J, Kim D, Chang C, Kim Y. 1998a. Self-oligomerization of NACP, the precursor protien of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett 421:73-76.
70. Paik S, Lee J, Kim D, Chang C, Kim Y. 1998b. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid observed in the presence of C-terminal A beta fragment (residues 25-35). FEBS Lett 421:73-76.
71. Paik SR, Shin HJ, Lee JH, Chang CS, Kim J. 1999. Copper(II) induced self-oligomerization of alpha-synuclein. Biochem J 340:821-828.
72. Pendleton RC, Parvez F, Sayed M, Hillman R. 2002. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther 300:91-96.
73. Perrin R, Woods W, Clayton D, George J. 2000. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids: structural analysis using site0directed mutagenesis. J Biol Chem 275:34393-34398.
74. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. 2000. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 18:417-421.
75. Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos E, Chandrasekharappa S, Athanassiadou A, Papapetropulos T, Johnson W, Lazzarini A, Duvoisin R, Di Iorio G, Golbe L, Nussbaum R. 1997. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
76. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J. 1999. Oxidatve damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Rad Biol Med 27:544-553.
77. Rochet J, Conway K, Lansbury PJ. 2000. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39:10619-10626.
78. Rockenstein E, Mallory, M, Hashimoto M, Song D, Shults C, Lang I, Masliah E. 2002. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the PDGF and Thy-1 promoters. J Neurosci Res 68:568-578.
79. Salmon D, Hansen L, Masliah E, Galasko D, Butters N, Katzman R. 1989. Neurophsychological characteristics of a Lewy body variant of Alzheimer's disease. Soc Neurosci Abstr 15:863.
80. Salmon D, Masliah E, DeTeresa R, Hansen L, Butters N, Katzman R, Terry R, 1990. Neuropsychological-neuropathological correlates in Alzheimer's disease. Soc Neurosci Abstr 16:148.
81. Samuel W, Alford M, Hofstetter R, Hansen L. 1997. Dementia with Lewy bodies versus pure Alzheimer's disease: differences in cognition, neurpathology; cholinergic dysfunction and synapse density. J Neuropathol Exp Neurol 56:499-508.
82. Selkoe D. 1989. Amyloid β protein precursor and the pathogenesis of Alzheimer's disease. Cell 58:611-612.
83. Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB, Haass C. 1996. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Ann NY Acad Sci 777:57-64.
84. Serpell L, Berriman J, Jakes R, Goedert M, Crowther R. 2000. Fiber diffraction of synthetic a-synuclein filaments shows amyloid-like cross-β conformation. Proc Natl Acad Sci 97:4897-4902.
85. Shastry BS. 2001. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 41:5-12.
86. Shimura H, Hattori N, Kubo S-i, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familialr Parkinson disease gene product, parkin, is a ubiquitinprotein ligase. Nature Gen 25:302-305.
87. Sisodia S, Price D. 1995. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J 9:366-370.
88. Souza J, Giasson B, Chen Q, Lee V-Y, Ischiropoulos H. 2000. Dityrosine cross-linking promotes formation of stable alphasynuclein polymers. J Biol Chem 275:18344-18349.
89. Spillantini M, Schmidt M, Lee V-Y, Trojanowski J, Jakes R, Goedert M. 1997. a-Synuclein in Lewy, bodies. Nature 388:839-840.
90. Suo Z, Fang C, Crawford F, Mullan M. 1997. Superoxide free radical and intracellular calcium mediate Abeta (1-42) induced endothelial toxicity. Brain Res 762:144-152.
91. Surguchov A, Surgucheva I, Solessio E, Baehr W. 1999. Synoretin:a new protein belonging to the synuclein family. Mol Cell Neurosci 13:95-103.
92. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH. 2000. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9:2683-2689.
93. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. 1998a. Abnormal accumulation of NACP/a-synuclein in neurodegenerative disorders. Am J Pathol 152:367-372.
94. Takeda A, Hashimoto M, Mallory M, Sundsmo M, Hansen L, Sisk A, Masliah E. 1998b. Abnormal distribution of the non-Ab component of Alzheimer's disease amyloid precursor/a-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 78:1169-1177.
95. Takeda A, Hashimoto M, Mallory M, Sundsmo M, Hansen L, Masliah E. 2000. C-terminal a-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders, Acta Neuropathol 99:296-304.
96. Trojanowski J, Lee V. 1998. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55:151-152.
97. Ueda K, Masliah E, Xia Y, Iwai A, Yoshimoto M, Saitoh T, 1993. Novel amyloid component (NAC) differentiates Alzheimer's disease from normal aging plaques. Soc Neurosei Abstr 19:1254.
98. Uversky VN, Li J, Souillac P, Jakes R, Goedert M, Fink AL. 2002. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 277:11970-11978.
99. van der Putten H, Wiederhold K, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren W, Ruegg M, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. 2000. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20:6021-6029.
100. Van Gool D, De Strooper B, Van Leuven F, Dom R, 1995. Amyloid precursor protein accumulation in Lewy dody dementia and Alzheimer's disease. Dementia 6:63-68.
101. Varadarajan S, Yatin S, Aksenova M, Butterfield DA, 2000. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184-208.
102. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT, Jr. 2001. Vesicle permeabilization by protofibrillar alpha-synuclein implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819.
103. Wakabayashi K, Hansen L, Masliah E. 1995. Cortical Lewy body-containing neurons are pyramidal cells: laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 89:404-408.
104. Wakabayashi K, Hansen L, Vincent I, Mallory M, Masliah E. 1997. Neurofibrillary tangles in the dentate granule cells in Alzheimer's disease, Lewy body disease and progressive supranuclear palsy. Acta Neuropathol 93:7-12.
105. Weinreb P, Zhen W, Pooh A, Conway K, Lansbury PJ. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochem 35:13709-13715.
106. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. alpha-Synuclein fibrillogenesis is nucleation dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274:19509-19512.
107. Yoshimoto M. Iwai A, Kang D, Otero D, Xia Y, Saitoh T. 1995 NACP, the precursor protein of non-amyloid b/A4 protein (Ab) component of Alzheimer disease amyloid, binds Ab and stimulates Ab aggregation. Proc Natl Acad Sci USA 92:9141-9145.
108. Zhou W, Hurlbert M, Schaack J, Prasad K, Freed C. 2000. Overexpression of human alpha-synuclein causes dopmaine neuron death in rat primary culture and immortalized mesence phalon-derived cells. Brain Res 866:33-4:3.